BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $546,808 | +5.3% | 20,736 | -31.3% | 0.00% | 0.0% |
| Q2 2023 | $519,371 | +1.0% | 30,196 | -2.6% | 0.00% | 0.0% |
| Q1 2023 | $513,996 | +4704.6% | 31,001 | +2108.0% | 0.00% | – |
| Q4 2022 | $10,698 | -43.7% | 1,404 | -28.4% | 0.00% | – |
| Q3 2022 | $19,000 | +11.8% | 1,961 | +6.7% | 0.00% | – |
| Q2 2022 | $17,000 | +112.5% | 1,838 | +148.4% | 0.00% | – |
| Q1 2022 | $8,000 | +700.0% | 740 | +972.5% | 0.00% | – |
| Q4 2021 | $1,000 | -66.7% | 69 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | -40.0% | 69 | -14.8% | 0.00% | – |
| Q2 2021 | $5,000 | +150.0% | 81 | +113.2% | 0.00% | – |
| Q1 2021 | $2,000 | – | 38 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |